Phaseline

Targets › TNFSF13

TNFSF13 (Tumor necrosis factor ligand superfamily member 13): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 4 Phase 2, 2 Phase 3, 1 Phase 1, 1 Phase 4; Genitourinary, Immunology, Oncology; next expected readout Jan 2027.

Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes. (UniProt, O75888)

Open in Phaseline: the race on TNFSF13, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tongji HospitalTelitacicept Freeze-dried powder Injection 80mg
TACI-Fc fusion protein targeting BLyS and APRIL
TNFSF13B, TNFSF13Phase 4Lupus or SLEMar 2027
OtsukaSibeprenlimab
Tumor necrosis factor ligand superfamily member 13 inhibitor
TNFSF13Phase 3Immunoglobulin A Nephropathy; Sjogren Disease; IgA NephropathyJan 2027
Vera TherapeuticsAtacicept
Tumor necrosis factor ligand superfamily member 13B inhibitor; Tumor necrosis factor ligand superfamily member 13 inhibitor
TNFSF13B, TNFSF13Phase 3IgA Nephropathy; IgA Nephropathy (IgAN); pMNSep 2027
Xuzhou Medical UniversityAPRIL-BAFF-Bicephali CAR-T cells
Dual-targeted CAR-T cell therapy against APRIL and BAFF ligands
TNFSF13, TNFSF13BPhase 1Multiple MyelomaJan 2027

Conditions

IgA Nephropathy (2) Multiple Myeloma (1) IgA Nephropathy (IgAN) (1) pMN (1) Lupus or SLE (1) Immunoglobulin A Nephropathy (1) Sjogren Disease (1)

Modalities

antibody (2), mixed (1)

Companies

Xuzhou Medical University (1) Vera Therapeutics (1) Tongji Hospital (1) Otsuka (1)

Related targets

TNFSF13B (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.